Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117081 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL14049050 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL4980169 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL331086 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL4980179 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL31454809 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL7668284 | 1.00 | NR1I2 (0.37) | NR1I2ALBPDE4DIRAK4 | |
| SCHEMBL9842434 | 0.83 | — | — | |
| SCHEMBL8446237 | 0.83 | — | — | |
| SCHEMBL8446236 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1982985-A2 | Method for manufacturing a purine derivative | Lonza AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-7358073-B2 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4- pyrimidinyl)-amino-2-cyclopentenyl-1-methanol | LONZA AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-7338945-B2 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R, 4S)-4(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino-2-cyclopentenyl-1-methanol | LONZA AG (CH) | 2008-03-04 | — | — | US | disclosed |
| US-7229981-B2 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S)-4-(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol | LONZA AG (CH) | 2007-06-12 | — | — | US | disclosed |
| US-7229981-B2 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S)-4-(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol | LONZA AG (CH) | 2007-06-12 | — | — | US | disclosed |
| US-20070123545-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | LONZA LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123545-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | LONZA LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123545-A1 | PROCESS FOR THE PREPARATION OF AMINOALCOHOL DERIVATIVES AND THEIR FURTHER CONVERSION TO (1R, 4S)-4(2-AMINO-6-CHLORO-5-FORMAMIDO-4- PYRIMIDINYL)-AMINO-2-CYCLOPENTENYL-1-METHANOL | GART, AASDHPPT, TYMS | NR1I2 1865/4885ALB 2272/4885PDE4D 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.